CRL
HealthcareCharles River Laboratories International, Inc.
Key Drivers
- Cash Generation
- Margin Pressure
- Rising Leverage
AIAI Summary
CRL should now be viewed as a cash-generative turnaround rather than a steady compounder, with the investment case hinging on whether management can deliver the promised $100M+ cost savings and 120–150 bps margin expansion in 2H before weak profitability, higher leverage, and a still-rich valuation punish any execution miss.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Margin Pressure
- •Rising Leverage
CRL is generating solid cash flow and maintaining workable liquidity, but recurring GAAP losses, weaker margins, rising leverage, and a stretched valuation keep the stock's risk-reward unattractive.
Price Behavior
Key Price Behavior Insights:
- •Bearish momentum
- •Broken support
- •Oversold bounce
CRL has rolled into a clear short-term downtrend over the last month, with a failed early-May breakout, broken support at $159-$166, and sellers still in control unless $150-$153 holds for an oversold bounce.
Early-May breakout failed after a peak at $185.39, followed by an almost 19% drop in eight sessions
Sentiment & News
Key News Insights:
- •Margin Pressure
- •Cautious Outlook
- •AI Expansion
Charles River's Q1 beat was offset by lower organic revenue, margin pressure and a cautious FY26 outlook, though guidance was reaffirmed and the company is expanding AI pathology and cell-therapy testing partnerships.
The news is mildly negative for CRL near term due to softer growth and guidance caution, but strategic investments in AI and cell therapy support longer-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings